Therapie von ZNS-Lymphomen |
| |
Authors: | PD Dr Agnieszka Korfel |
| |
Institution: | 1. Klinik für H?matologie und Onkologie, Charité ??Universit?tsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Deutschland
|
| |
Abstract: | Primary central nervous system lymphoma (PCNSL) differs from nodal lymphoma with similar histological findings, usually diffuse large B-cell lymphoma, by its strong affinity for the central nervous system (CNS), aggressive course and unusual sensitivity to high-dose methotrexate (HDMTX). Thus, primary therapy of PCNSL is currently based on HDMTX but the optimal chemotherapy regimen has not yet been defined due to the rarity of this disease. In younger patients a cure should be the goal and thus intensified chemotherapy protocols should be considered. Whole brain irradiation does not prolong overall survival when used in primary therapy and thus should not be used routinely. Similar to PCNSL the infrequent CNS involvement of a systemic lymphoma, also called secondary CNS lymphoma, has a very poor prognosis. The scarce data suggest a role for HDMTX-based systemic chemotherapy and high-dose chemotherapy followed by stem cell transplantation for outcome improvement. Avoidance of late neurotoxicity is an important goal in the treatment of PCNSL. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|